<DOC>
	<DOCNO>NCT00093210</DOCNO>
	<brief_summary>The primary objective clinical research study establish bioequivalence 2 treatment , rFIX rFIX-R , give 10-minute intravenous bolus infusion .</brief_summary>
	<brief_title>Study Evaluating Recombinant Human Factor IX ( BeneFIX ) New Formulation BeneFIX ( rFIX-R ) Moderate Severe Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Moderate severe hemophilia B ( FIX : C ≤2 % ) Previously treat patient ( PTPs ) ≥150 document exposure day Age ≥ 12 year ( US sit ) Detectable factor IX inhibitor define ≥0.6 Bethesda Units pool plasma report local laboratory ( family history inhibitor exclude patient ) Patient history factor IX inhibitor replacement therapy Patient unable factor IX replacement therapy least 5 day without bleed</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>